NOVEL RNA INTERFERENCE SCREENING TECHNIQUE IDENTIFIES POSSIBLE PATH FOR MALIGNANT GLIOMA TREATMENT
Monday, May 24, 2010
FOR IMMEDIATE RELEASE
Contact: Public Affairs and Publications
WORCESTER, Mass.— Researchers at UMass Medical School report in the journal Nature Medicine on a cellular pathway in the deadly brain cancer malignant glioma, a pathway essential to the cancer’s ability to grow – and a potential target for therapy that would stop the cancer’s ability to thrive.
In the paper “A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications,” appearing this week as an Advanced Online Publication, Michael R. Green, MD, PhD, Howard Hughes Medical Institute Investigator, the Lambi and Sarah Adams Chair in Genetic Research and professor of molecular medicine and biochemistry & molecular pharmacology and colleagues use a genome-wide RNAi screening tool to identify a dozen genes that affect the function of a crucial protein necessary for glioma cells to grow; further research found a key pathway that appears in laboratory cultures and mouse models to be susceptible to two cancer drugs already in use for other types of cancer.
A hallmark of cancer is uncontrolled cell growth, often caused by overexpression of genes that help cells survive, or underexpression of those genes that induce normal cell death. Genes that are expressed highly in cancer cells and are essential for their survival are appealing targets for drug therapy.
Green’s lab has in recent years developed a clever way of scanning the genome to identify genes that appear to promote the natural process of programmed cell death called “apoptosis”, or that inhibit the growth of cells; Green and colleagues used a technique called genome-wide RNA interference screening—to identify novel genes that regulate the expression of a transcription factor called ATF5 in malignant glioma cells. The discovery of at least one previously unknown genetic pathway that appears to regulate this key transcription factor, and the subsequent determination that the cancer drugs sorafenib and temozolomide inhibit glioma growth point to dramatic new possibilities for potential therapeutics and are exciting advances at the frontier of cancer biology and genetic expression.
ATF5 was first identified as an important pro-survival factor by Dr. Green in 2002.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu.